NeuroPace, Inc. (NPCE) Financial Analysis & Valuation | Quarter Chart
NeuroPace, Inc. (NPCE)
NPCEPrice: $14.26
Fair Value: 🔒
🔒score
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system ... more
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS... more
Description
Shares
| Market Cap | $480.09M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Joel D. Becker |
| IPO Date | 2021-04-22 | CAGR | 0.18% |
| Employees | 184 | Website | www.neuropace.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 11.6% | Total Yield | 11.6% |
NPCE chart loading...
Fundamentals
Technicals
| Enterprise Value | $569.83M | P/E Ratio | -21.61 |
| Forward P/E | -40.36 | PEG Ratio | — |
| P/S Ratio | 4.26 | P/B Ratio | 22.02 |
| P/CF Ratio | -38.07 | P/FCF Ratio | -37.94 |
| EPS | $-0.66 | EPS Growth 1Y | -30.53% |
| EPS Growth 3Y | -65.62% | EPS Growth 5Y | -62.13% |
| Revenue Growth 1Y | 25.13% | Gross Margin | 0.77% |
| Operating Margin | -0.16% | Profit Margin | -0.32% |
| ROE | -1.57% | ROA | -0.3% |
| ROCE | -0.19% | Current Ratio | 5.28 |
| Quick Ratio | 4.33 | Cash Ratio | 1.22 |
| Debt/Equity | 3.72 | Interest Coverage | -1 |
| Altman Z Score | -2.78 | Piotroski Score | 3 |